SPL 3.00% 9.7¢ starpharma holdings limited

Merck’s anti-viral development., page-2

  1. 3,449 Posts.
    lightbulb Created with Sketch. 820
    Even one of our partners are doing human clinical trials for COVID-19 therapies (treatment). Zero comments so far …

    • A human trial for an oral antiviral
    • Possible FDA authorisation 2H 2021
    • US Government orders pending
    • Massive BARDA grant pending
    • Established licencing agreements for manufacture
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.